CMV IgG Test

Most adults carry cytomegalovirus (CMV) and will never know it. The initial infection usually passes without symptoms, but the virus never leaves. It hides in your cells for life, and your immune system spends real resources keeping it in check. Over decades, that ongoing effort reshapes your immune system in ways that standard blood panels never reveal.

CMV IgG (cytomegalovirus immunoglobulin G) is the antibody your body produces in response to CMV infection. A positive result means you have been infected at some point. But the number itself, not just whether it is positive or negative, may carry information about how hard your immune system is working to contain the virus and how that burden connects to aging, inflammation, and long-term health.

What CMV IgG Tells You

This test measures the concentration of IgG antibodies your body has built against CMV. IgG is the most abundant antibody type in your blood, and once your immune system produces CMV-specific IgG, those antibodies persist indefinitely. A positive result confirms past infection. A negative result means you have never been exposed and remain susceptible to a first infection.

The test is qualitative at its core: positive or negative. But the quantitative level matters too. Higher antibody concentrations appear to reflect more intense or frequent viral reactivation events, even when you feel perfectly fine. Think of the antibody level as a rough gauge of how actively your immune system is wrestling with the virus behind the scenes.

How Common Is CMV Infection?

CMV is one of the most widespread human infections on the planet. A global meta-analysis estimated seroprevalence at 83%. In the United States, NHANES data show that about 50% of adults aged 6 to 49 have been infected. That number climbs steeply with age: roughly 36% of children aged 6 to 11 are seropositive, compared to over 90% of adults aged 80 and older.

Infection rates also vary by race, ethnicity, and socioeconomic factors. NHANES found seroprevalence of 51.2% in non-Hispanic white adults, 75.8% in non-Hispanic Black adults, and 81.7% in Mexican American adults. Women tend to have higher rates than men at every age. Low household income, crowded living conditions, and foreign birthplace are all independently associated with higher seroprevalence.

All-Cause Mortality

Several large studies have examined whether CMV seropositivity, and particularly high antibody levels, predict an increased risk of dying from any cause. The evidence is mixed but leans toward a real association, especially in older adults and when antibody levels are high rather than simply positive.

The EPIC-Norfolk study followed over 13,000 adults for an average of 14.3 years. CMV-seropositive individuals had a 16% higher risk of all-cause mortality compared to seronegative individuals (about 1.2 times the risk), and the risk climbed with higher antibody levels. This held up after adjusting for socioeconomic status and other confounders.

In the Sacramento Area Latino Study on Aging, which followed about 1,470 older Latino adults for 9 years, those in the highest quartile (top 25%) of CMV IgG had about 43% higher all-cause mortality after full statistical adjustment. Inflammatory markers (TNF-alpha and IL-6) appeared to explain roughly 19% of that increased risk, suggesting chronic inflammation is part of the mechanism.

The Women's Health and Aging Studies found an even sharper signal in older women aged 70 to 79: after adjusting for confounders, those in the highest quartile of CMV antibodies were about 2.8 times as likely to die within 5 years. Before adjustment, they were also about 3.5 times as likely to become frail, though this frailty association did not remain statistically significant after full adjustment.

On the other hand, a meta-analysis pooling five European cohorts of over 10,000 older white adults found that the association between CMV seropositivity and mortality lost statistical significance after adjusting for confounders. The highest antibody quartile showed a trend toward increased risk (about 13% higher), but the result was not definitive. Two UK Biobank analyses also found no significant link between CMV seropositivity and all-cause mortality in middle-aged adults after full adjustment.

Sources: EPIC-Norfolk (Gkrania-Klotsas et al., 2013); Sacramento Area Latino Study on Aging (Roberts et al., 2010); Women's Health and Aging Studies (Wang et al., 2010)

What this means for you: the strongest evidence connects high CMV IgG levels, not just seropositivity, to mortality risk in older populations. If you are under 60 and otherwise healthy, the link is weaker and less consistent. But if you are older or have other risk factors, a high antibody level is worth tracking alongside inflammatory markers.

Heart Disease

The EPIC-Norfolk cohort also examined heart disease specifically. Among over 12,500 adults without prior heart disease, those with the highest CMV antibody levels had about a 22% increased risk of developing ischemic heart disease (reduced blood flow to the heart) over 12 years. This association persisted after adjusting for standard cardiac risk factors, social class, and inflammation.

However, the UK Biobank told a different story. In a study of over 8,500 adults aged 40 to 69 followed for about 10 years, there was no significant association between CMV seropositivity and cardiovascular disease, heart disease, or stroke, even when analyzed by antibody level. An updated 2025 analysis using more rigorous statistical methods confirmed the null finding.

The Busselton Health Survey in Australia, which tracked 2,050 adults for 20 years, found a marginally significant link between CMV antibody levels and all-cause death, but no significant connection to cardiovascular death, acute heart events, or major cardiovascular complications.

The picture that emerges is unresolved. CMV may contribute to cardiovascular risk through chronic inflammation, but the evidence does not yet support using CMV IgG as a standalone cardiac risk marker. Its value may lie more in the broader context of immune aging than in predicting heart attacks specifically.

Immune Aging and Inflammation

This is where CMV IgG connects most directly to the longevity conversation. Your immune system has a finite capacity, and CMV occupies a growing share of it over time. Higher CMV antibody levels are linked to expansion of a specific type of immune cell (CD8+ T cells that have reached the end of their functional lifespan), reduced ratios of helper to killer T cells, and higher levels of inflammatory proteins like IL-6 (interleukin-6, a signaling molecule that promotes inflammation) and soluble TNF receptor I (a marker of immune activation).

A study of immune profiles across the lifespan found that anti-CMV antibody levels organize human immune systems into distinct clusters. High-antibody individuals showed more pronounced age-related immune changes regardless of their chronological age. In healthy adults, CMV seropositivity was associated with an average epigenetic age (a measure of biological aging based on DNA modifications) of 65.3 years, compared to 59.5 years in seronegative individuals.

The MARK-AGE study found that the highest CMV IgG quartile was associated with lower antioxidant levels, higher markers of oxidative stress (damage from reactive oxygen molecules), and a greater prevalence of cardiovascular disease and diabetes. While this does not prove CMV causes these conditions, it reinforces the pattern: a high CMV antibody level is a signal that your immune system is under chronic strain.

Congenital Infection and Pregnancy

CMV is the most common congenital infection, affecting 0.2% to 2.2% of newborns worldwide. If a woman is infected with CMV for the first time during pregnancy (primary infection), the risk of transmitting the virus to the fetus is 30% to 40%, and the consequences can be severe: hearing loss, intellectual disability, and other neurological problems. CMV IgG testing in pregnancy is used to determine whether a woman has been previously exposed or is at risk for a first infection.

A negative CMV IgG before or early in pregnancy identifies a woman who has never been exposed. If she later develops symptoms or has a known CMV exposure, repeat testing can detect new antibodies (seroconversion), which would indicate primary infection. Routine universal screening in pregnancy is not currently recommended in the U.S., though Italy introduced universal screening in December 2023 based on emerging evidence that antiviral treatment during early primary infection can reduce transmission to the fetus.

Transplant Risk Stratification

CMV IgG testing is standard practice before organ or bone marrow transplantation. The donor and recipient serostatus combination determines the risk of CMV disease after transplant. The highest-risk scenario is a seropositive donor giving an organ to a seronegative recipient (D+/R-), because the recipient has no pre-existing immunity and may develop severe CMV disease when the virus reactivates from the transplanted organ.

Among seropositive transplant recipients, higher pre-transplant CMV IgG levels predict a greater likelihood of reactivation. One study of stem cell transplant recipients found reactivation rates of 81% in high-titer recipients versus 37% in low-titer recipients and 16% in seronegative patients. High pre-transplant antibody levels were also associated with worse overall survival at 36 months.

Reference Ranges

CMV IgG is primarily a qualitative test: the main question is whether you are positive or negative. Each lab platform uses its own units and cutoffs, and values are not interchangeable between platforms. There is no WHO international standard for CMV IgG (unlike CMV viral load, which has been standardized). This is a significant limitation: a value of 6.0 AU/mL on one platform has no direct equivalent on another.

These cutoffs determine seropositive vs. seronegative status. Your lab may use slightly different thresholds depending on their platform. For the quantitative level (how high your antibodies are), there are no standardized clinical tiers like "optimal" or "elevated." Research studies have used within-study quartiles to identify risk gradients, with the highest quartile consistently showing the worst outcomes, but these quartiles are study-specific and not transferable as universal cutpoints.

Tracking Your Trend

A single CMV IgG result gives you one key piece of information: have you been exposed or not? For most seropositive people, one test answers that question permanently. Your IgG is not going to turn negative. So the value of repeat testing is different from most biomarkers.

If you are interested in the quantitative level as a window into immune aging, repeat measurements must be done using the same laboratory and the same assay platform. Different immunoassays can produce values that vary by up to 185-fold for the same blood sample. Comparing a result from Abbott Architect to one from Roche Elecsys is meaningless. Stick with one lab.

For those tracking CMV IgG as part of a broader longevity panel, a reasonable approach is to establish a baseline, then recheck every 1 to 2 years using the same assay. A rising titer over time may reflect more frequent subclinical viral reactivation, which in turn may signal increasing immune strain. Pair it with inflammatory markers like hs-CRP and immune cell panels to build a more complete picture of how your immune system is aging.

If you are seronegative, the value of repeat testing is to catch a new infection early, which matters most during pregnancy, before transplantation, or if you develop an immunocompromising condition.

When Results Can Be Misleading

The biggest source of error with CMV IgG is not biological fluctuation but assay variability. Unlike metabolic markers that bounce around with meals, stress, or exercise, CMV IgG is remarkably stable in immunocompetent people. Your antibodies do not shift meaningfully with fasting state, time of day, recent workouts, or acute dietary changes. That stability is one of the test's strengths.

Where results can mislead:

• Blood transfusions and immunoglobulin therapy: receiving blood products can transfer donor antibodies into your system, producing a false-positive result. One study found that up to 24% of patients classified as CMV-seropositive before transplant were actually seronegative when baseline serology was re-examined. If you have received transfusions recently, discuss this with the ordering provider.
• Immunosuppression: people on intensive immunosuppressive therapy or with severe immune deficiency may not produce enough antibodies to test positive, even though they carry latent CMV. This can produce a dangerous false-negative result. Conversely, CMV reactivation in transplant patients can push antibody levels higher, which reflects real viral activity rather than a testing artifact.
• Switching lab platforms: comparing numerical values across different assay systems is unreliable. A 185-fold variation between platforms for the same sample has been documented. Always retest with the same lab and assay when monitoring trends.
• Infants under 12 months: a positive CMV IgG in a baby may reflect maternal antibodies that crossed the placenta during pregnancy, not the baby's own infection.

Complement proteins (part of the immune system) can occasionally interfere with certain assay platforms, particularly the VIDAS system, producing falsely low readings during acute infections. This is an uncommon technical issue that can be corrected in the laboratory.